Westin, Johan

Publishing since 1999 (Senior)

Has published 39 publications in 12 years

Number of publications published per year by Westin, Johan. (Source : PubMed)

Distribution of publications types for Westin, Johan. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK, Durie B. Survival and years of life lost in different age cohorts of patients with multiple myeloma.  J. Clin. Oncol.  2010;28;9  
•  Brittain-Long R, Westin J, Olofsson S, Lindh M, Andersson LM. Prospective evaluation of a novel multiplex real-time PCR assay for detection of fifteen respiratory pathogens-duration of symptoms significantly affects detection rate.  J. Clin. Virol.  2010;47;3  
•  Westin J, Hellstrand K, Dhillon AP, Lagging M. Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?  J. Viral Hepat.  2010  
•  Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Westin J, Hellstrand K, Norkrans G, Lagging M. Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?  Clin. Infect. Dis.  2010;50;4  
•  Turesson I, Westin J. [Diagnosis and follow up of patients with small M components. With the view to avoid transformation to malignant disease]  Lakartidningen  2010;107;4  
•  Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.  Hepatology  2009  
•  Gunnarsdottir SA, Olsson R, Olafsson S, Cariglia N, Westin J, Thjódleifsson B, Björnsson E. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes.  Scand. J. Gastroenterol.  2009;44;8  
•  Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.  Hepatology  2008;48;2  
•  Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Norkrans G. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.  Hepatology  2008;47;6  
•  Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.  Blood  2008;111;8  

[ See timeline ] [ See all publications ]